摘要
探讨晚期非小细胞肺癌不同化疗方案临床疗效和经济学效果。将晚期非小细胞肺癌患者根据不同治疗方案分为4组。PC方案：紫杉醇175mg.m^-2,iv,d1;卡铂AUC=5,iv,d2。NP方案：长春瑞滨25mg.m^-2,iv,d1,8;顺铂30mg.m^-2,iv,d2-4。GP方案：吉西他滨1250mg.m^-2,iv,d1,8;顺铂75mg.m^-2,iv,d1。TP方案：多西他赛60mg.m^-2,iv,d1;顺铂30mg.m^-2,iv,d1-3。4组方案均以21d为一个周期。运用药物经济学成本-效果分析方法,对4组治疗方案进行分析、评价。结果表明,PC方案、NP方案、GP方案和TP方案的有效率分别为47.2%、31.7%、44.4%和39.3%。化疗一个疗程住院费用分别为8781.67元、6717.88元、13371.29元和10671.90元。在NP方案的基础上,每增加一个单位效果,PC方案、GP方案和TP方案所追加的成本分别为133.15元、523.89元和520.27元。本文研究结果提示,PC方案为晚期非小细胞肺癌化疗的较好方案。
The clinical result and economic effectiveness of four different chemotherapy regimens in the treatment of non＇small-cell lung cancer was discussed. The cases of non-small-cell lung cancer are divided into four groups according to the different chemotherapy regimens applied. PC scheme, paclitaxel 175mg· m^-2, iv, dl- carboplatin AUC=5, iv, d2. NP scheme, vinorelbine 25mg. m^-2, iv, dl, 8; cisplatin 30mg·m^-2, iv, d2-4. GP scheme, gemcitadine 1250mg·m^-2, iv, d1, 8; cisplatin 75 mg·m^-2, iv, dl. TP scheme, docetaxel 60 mg·m^-2, iv, d1 cisplatin 30mg·m^-2, iv, d1-3. The four regimens all take 21 days as one cycle. The regimens of four groups are compared and assessed by using pharmaceutical economics cost- effectiveness analytical method. The result indicates that the effective rates were 47. 2%, 31.7%, 44.4% and 39.3% for PC scheme, NP scheme, GP scheme and TP scheme respectively. The cost of each chemotherapy treatment in hospital was 8781.67, 6717.88, 13371.29 and 10671.90 Yuan respectively. On the basis of NP scheme group, each extra effective unit caused PC scheme group, GP scheme group and TP scheme group increase 133. 15, 523. 89 and 520. 27 Yuan respectively as supplementary. As the prompt of the analysis of this article, PC scheme is the preferable chemotherapy regimen for non--small--cell lung cancer.
出处
《中国药事》
CAS
2007年第3期204-207,共4页
Chinese Pharmaceutical Affairs
关键词
非小细胞肺癌
化疗方案
成本-效果分析
non--small--cell lung cancer
chemotherapy regimen~ cost--effectiveness analysis
